| Arena Pharmaceuticals is a biopharmaceutical company focused on delivering medicines with pharmacology and pharmacokinetics to patients globally. Co.'s clinical programs include: etrasimod (APD334), which is being evaluated in ulcerative colitis, a program for Crohn's disease, as well as a program for atopic dermatitis; olorinab (APD371), which is is being evaluated for a range of visceral pain conditions associated with gastrointestinal diseases and for treatment of abdominal pain associated with irritable bowel syndrome; and APD418, which is being evaluated in a trial for acute heart failure. We show 15 historical shares outstanding datapoints in our ARNA shares outstanding history coverage, used to compute ARNA market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ARNA market cap history over the course of time is important for investors
interested in comparing ARNA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ARNA versus a peer is one thing; comparing
ARNA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ARNA can fluctuate over the course of history.
With this page we aim to empower investors researching ARNA by allowing them to research the ARNA market cap history.